Improving awareness could transform outcomes in degenerative cervical myelopathy [AO Spine RECODE-DCM Research Priority Number 1]

BM Davies, O Mowforth, H Wood, Z Karimi… - Global spine …, 2022 - journals.sagepub.com
Study Design Literature Review (Narrative) Objective To introduce the number one research
priority for Degenerative Cervical Myelopathy (DCM): Raising Awareness. Methods Raising …

A minimum data set—Core outcome set, core data elements, and core measurement set—For degenerative cervical myelopathy research (AO Spine RECODE DCM) …

BM Davies, X Yang, DZ Khan, OD Mowforth… - PLoS …, 2024 - journals.plos.org
Background Degenerative cervical myelopathy (DCM) is a progressive chronic spinal cord
injury estimated to affect 1 in 50 adults. Without standardised guidance, clinical research …

Riluzole for degenerative cervical myelopathy: a secondary analysis of the CSM-PROTECT Trial

MG Fehlings, KM Pedro, MA Alvi… - JAMA network …, 2024 - jamanetwork.com
Importance The modified Japanese Orthopaedic Association (mJOA) scale is the most
common scale used to represent outcomes of degenerative cervical myelopathy (DCM); …

Machine learning-based cluster analysis identifies four unique phenotypes of patients with degenerative cervical myelopathy with distinct clinical profiles and long …

KM Pedro, MA Alvi, N Hejrati, AI Quddusi, A Singh… - …, 2024 - thelancet.com
Background Degenerative cervical myelopathy (DCM), the predominant cause of spinal cord
dysfunction among adults, exhibits diverse interrelated symptoms and significant …

Cervical spondylotic myelopathy with severe axial neck pain: is anterior or posterior approach better?

AK Chan, CI Shaffrey, ON Gottfried, C Park… - … of Neurosurgery: Spine, 2022 - thejns.org
OBJECTIVE The aim of this study was to determine whether multilevel anterior cervical
discectomy and fusion (ACDF) or posterior cervical laminectomy and fusion (PCLF) is …

Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo …

MG Fehlings, JH Badhiwala, H Ahn… - The Lancet …, 2021 - thelancet.com
Background Degenerative cervical myelopathy represents the most common form of non-
traumatic spinal cord injury. This trial investigated whether riluzole enhances outcomes in …

Clinical outcome measures and their evidence base in degenerative cervical myelopathy: a systematic review to inform a core measurement set (AO Spine RECODE …

AY Touzet, A Bhatti, E Dohle, F Bhatti, KS Lee… - BMJ open, 2022 - bmjopen.bmj.com
Objectives To evaluate the measurement properties of outcome measures currently used in
the assessment of degenerative cervical myelopathy (DCM) for clinical research. Design …

Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial—study protocol

B Davies, OD Mowforth, S Yordanov… - BMJ open, 2023 - bmjopen.bmj.com
Introduction Degenerative cervical myelopathy (DCM) is a common and disabling condition
of symptomatic cervical spinal cord compression secondary to degenerative changes in …

Develo** peri-operative rehabilitation in degenerative cervical myelopathy [AO Spine RECODE-DCM Research Priority Number 6]: an unexplored opportunity?

TF Boerger, AS Hyngstrom, JC Furlan… - Global spine …, 2022 - journals.sagepub.com
Study Design Narrative review. Objective Degenerative cervical myelopathy is one of the
most frequent impairments of the spinal cord encountered internationally in adults. Currently …

Outcomes of degenerative cervical myelopathy from the perspective of persons living with the condition: findings of a semistructured interview process with partnered …

BM Davies, C Munro, DZ Khan… - Global Spine …, 2022 - journals.sagepub.com
Study Design: Mixed-methods cross-sectional study. Objectives: Degenerative cervical
myelopathy (DCM) is a common and disabling condition. While classically, assessment and …